Sangamo gains on Phase I/II readout for hemophilia A gene therapy

Interim Phase I/II data for Sangamo’s hemophilia A gene therapy Tuesday helped shares of the company complete a round-trip from its 31% tumble on a February readout for its mucopolysaccharidosis therapies. Sangamo

Read the full 320 word article

User Sign In